Laryngeal Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Laryngeal Cancer – Drugs In Development, 2023’, provides an overview of the Laryngeal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Laryngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Laryngeal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Laryngeal Cancer
- The report reviews pipeline therapeutics for Laryngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Laryngeal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Laryngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Laryngeal Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Laryngeal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Laryngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbVie Inc
Advenchen Laboratories LLC
Akeso Inc
Angel Pharmaceuticals Inc
Ascendis Pharma AS
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
BeiGene Ltd
Bicara Therapeutics Inc
BioAtla Inc
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
Compass Therapeutics Inc
Compugen Ltd
CSPC Pharmaceutical Group Ltd
Cyclacel Pharmaceuticals Inc
Dragonfly Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
FUDA Cancer Hospital
Genentech USA Inc
Gilead Sciences Inc
GSK plc
I-Mab
Icahn School of Medicine at Mount Sinai
Incyte Corp
Innolake Biopharm Co Ltd
Innovent Biologics Inc
IO Biotech Inc
Janssen Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Laboratoires Pierre Fabre SA
Lisata Therapeutics Inc
Mabpharm Ltd
Merck & Co Inc
Merck KGaA
Moderna Inc
Natco Pharma Ltd
NeoImmuneTech Inc
Novartis AG
Nubiyota LLC
Nykode Therapeutics ASA
Pfizer Inc
POINT Biopharma Global Inc
Prelude Therapeutics Inc
Puretech Health Plc
QBiotics Group Ltd
Rapa Therapeutics LLC
Regeneron Pharmaceuticals Inc
Release Therapeutics
Revolution Medicines Inc
Sanofi
Scancell Holdings Plc
Seagen Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Sichuan Ankekang Biomedical Co Ltd
SinoCelltech Group Ltd
Systimmune Inc
UNC Lineberger Comprehensive Cancer Center
Vaccinex Inc
VasGene Therapeutics Inc
Zhuhai Beihai Biotech Co Ltd